The SPORE in Breast Cancer
Vanderbilt-Ingram Cancer Center' s SPORE in Breast Cancer, established in 2003, is one of only six in the country, and focuses on innovative, translational research for better diagnosis, prognosis, screening, prevention and treatment of breast cancer.
The Vanderbilt-Ingram Cancer Center SPORE in Breast Cancer has established a true multidisciplinary program focused on conducting multidisciplinary, mechanism-based, translational research of the highest possible impact that will contribute meaningfully to measurable progress in breast cancer. Our investigators have expertise in cellular signaling and molecular biology, breast pathology, medical, surgical, and radiation oncology, clinical trial design, epidemiology and population studies, mass spectrometry, biostatistics, and biomedical informatics.
The Breast SPORE supports several initiatives including four scientific research projects, five cores that provide essential services to SPORE projects, a developmental research program to support pilot projects, and career development opportunities for physician-scientists in training.
Breast SPORE Research Projects
The SPORE in Breast Cancer supports four research projects aimed at addressing basic, clinical and population research questions of importance in human breast cancer. All projects are translational and multidisciplinary and are led by co-investigators from multiple departments across the School of Medicine, with complementary basic science and translational/clinical expertise.
Learn more about our Breast SPORE research projects and cores.
Inhibition of PI3 kinase as a strategy to abrogate antiestrogen resistance in breast cancer
- Carlos L. Arteaga, MD, Principal Investigator
- Ingrid A. Mayer, MD, Project Co-Leader
Strategies to improve outcomes for triple negative breast cancer patients involving subtype-specific targeted therapies and genomic discovery
- Jennifer Pietenpol, PhD., Project Leader
- Vandana Abramson, MD, Project Co-Leader
Mcl-1 inhibitors for the treatment of breast cancer
- Rebecca Cook, PhD, Project Co-Leader
- Stephen Fesik, PhD, Project Co-Leader
- Melinda Sanders, MD, Project Co-Leader
The obesity-metabolic biomarker axis and breast cancer risk
- William Blot, PhD, Project Co-Leader
- Loren Lipworth, ScD, Project Co-Leader
- Wei Zheng, MD, PhD, Project Co-Leader
The Developmental Research Program (DRP) supports pilot projects that allow early, high-risk research to move solid basic science findings toward clinical application, as well as the migration of provocative clinical observations back to the laboratory in order to understand their mechanistic basis.
The main criteria for selection and funding of developmental (pilot) projects include scientific merit, relevance to mammary biology and/or breast cancer, collaboration and potential for extramural peer-reviewed funding. There also is an emphasis on utilization of emerging technologies and on young investigators.
The aims of this program are:
- To support junior and established investigators conducting high-risk, innovative research applicable to breast cancer
- To support mechanistic investigation in the laboratory of provocative clinical observations
- To support progression of DRP projects to extramural funding and peer-reviewed publications
- To focus on emerging technologies and approaches applicable to translational research in breast cancer
Learn more about our Breast SPORE Funding Opportunities as well as funding through other programs.
Improving the quantity and quality of opportunities for training in translational research is of vital importance for the success of the Breast SPORE as well as for the successful application of progress made in the laboratory to our ultimate goal: a reduction in the incidence, morbidity and mortality resulting from breast cancer.
The Career Development Program achieves these goals by:
- The recruitment, support and development of young physician-scientists and laboratory-based translational/clinical investigators (MD and MD/PhD) into breast cancer research
- The recruitment, support and development of young basic scientists (PhD) into mechanism-based applied research in breast cancer
- Recruiting outstanding basic scientists into breast cancer research and providing clinical and translational expertise to this research
- Providing translational research mentorship, training, and opportunities for investigators to develop the knowledge, skills and expertise to successfully pursue independent, extramurally-funded scholarly careers focused in translational research in breast cancer
- Recruiting women and underrepresented minority investigators into research in breast cancer
Gene expression in triple-negative breast cancer in relation to survival.
Wang S, Beeghly-Fadiel A, Cai Q, Cai H, Guo X, Shi L, Wu J, Ye F, Qiu Q, ZhengY, Zheng W, Bao PP, Shu XO.
Breast Cancer Res Treat. 2018 May 10. PMID: 29748761.
Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival.
Werfel TA, Wang S, Jackson MA, Kavanaugh TE, Joly MM, Lee LH, Hicks DJ, Sanchez V, Ericsson PG, Kilchrist KV, Dimobi SC, Sarett SM, Brantley-Sieders DM, Cook RS, Duvall CL.
Cancer Res. 2018 Apr 1;78(7):1845-1858. PMID: 29358172
Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers.
Williams MM, Lee L, Werfel T, Joly MMM, Hicks DJ, Rahman B, Elion D, McKernan C, Sanchez V, Estrada MV, Massarweh S, Elledge R, Duvall C, Cook RS.
Cell Death Dis. 2018 Jan 17;9(2):21. PMID: 29343814
DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer.
Luo N, Nixon MJ, Gonzalez-Ericsson PI, Sanchez V, Opalenik SR, Li H, Zahnow CA, Nickels ML, Liu F, Tantawy MN, Sanders ME, Manning HC, Balko JM.
Nat Commun. 2018 Jan 16;9(1):248. PMID: 29339738
PIK3CA C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3Kα Inhibitors.
Croessmann S, Sheehan JH, Lee KM, Sliwoski G, He J, Nagy R, Riddle D, Mayer IA, Balko JM, Lanman R, Miller VA, Cantley LC, Meiler J, Arteaga CL.
Clin Cancer Res. 2018 Mar 15;24(6):1426-1435. PMID: 29284706
View the full list of VICC Breast SPORE publications in PubMed
Since 2004, research advocates have been an integral part of the Breast SPORE team, offering patient experiences and perspectives into all aspects of breast cancer research at Vanderbilt-Ingram. These passionate, determined and dedicated volunteers are actively involved helping to bring the best science to those who are affected by breast cancer by contributing in the following ways:
- Attend monthly Breast Cancer Programs and SPORE seminars
- Serve on SPORE executive committee
- Attend project meetings as part of the interdisciplinary team and participate in research discussions
- Review and provide input on research development, design, clinical trials and informed consents
- Develop patient-oriented resources and tools for SPORE clinical trials
- Raise awareness through presentations to patient and community groups
- Facilitate collaborations with local, regional, and national organizations dedicated to breast cancer
- Participate in on-going advocate educational sessions
Meet the Breast SPORE Advocates
Contact the Breast SPORE Team
- For research/medical questions, contact one of the principal investigators: Jennifer Pietenpol, Ph.D., or Ingrid Mayer, M.D., M.S.C.I.
- For questions about our research advocacy program, contact Stephanie Elliott, M.P.H., Program Manager.
- For questions about SPORE grant pilot funding, contact Julie Schaum, M.S., Associate Director of Research Administration.
Breast SPORE News
Study seeks to boost breast tumor immune response
Breast SPORE Seminars & Events
20 September 2018
08 November 2018